



Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer


SUPPLEMENTARY MATERIALS



Supplementary Figure 1: GSK-J4 treatment represses PCa cells proliferation. Analysis of cell morphology in control-treated or GSK-J4-treated (6 μ M for 72h) cells.



Supplementary Figure 2: Analysis of JMJD3 and UTX levels. Western blot analysis of JMJD3 and UTX. Beta-actin for loading normalization.



Supplementary Figure 3: Proliferation of cells treated with Cabazitaxel. ED50 of Cabazitaxel was determined for R1-AD1, R1-D567 and R1-I567 cells.